Medication for Acromegaly Reduces Expression of MUC16, MACC1 and GRHL2 in Pituitary Neuroendocrine Tumour Tissue

Acromegaly is a disease mainly caused by pituitary neuroendocrine tumor (PitNET) overproducing growth hormone. First-line medication for this condition is the use of somatostatin analogs (SSAs), that decrease tumor mass and induce antiproliferative effects on PitNET cells. Dopamine agonists (DAs) ca...

詳細記述

保存先:
書誌詳細
出版年:Front Oncol
主要な著者: Saksis, Rihards, Silamikelis, Ivars, Laksa, Pola, Megnis, Kaspars, Peculis, Raitis, Mandrika, Ilona, Rogoza, Olesja, Petrovska, Ramona, Balcere, Inga, Konrade, Ilze, Steina, Liva, Stukens, Janis, Breiksa, Austra, Nazarovs, Jurijs, Sokolovska, Jelizaveta, Pirags, Valdis, Klovins, Janis, Rovite, Vita
フォーマット: Artigo
言語:Inglês
出版事項: Frontiers Media S.A. 2021
主題:
Oncology
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7928352/
https://ncbi.nlm.nih.gov/pubmed/33680922
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.593760
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料